Gentium S.p.a. (GENT) Return on Investment ROI from the fourth quarter of 2013 to fourth quarter of 2012 and for the year 2013, average high and low, overall ranking from Dec 31 2013 to Dec 31 2012 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Gentium S.p.a.  (GENT)


Gentium S.p.a.'s ROI from its fourth quarter of 2013 to the fourth quarter of 2012 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Gentium S.p.a.'s ROI in the fourth quarter of 2013?
Gentium S.p.a. achieved a return on average invested assets (ROI) of 89.96 % in its fourth quarter of 2013, this is above GENT's average return on investment of -38.92%.
Gentium S.p.a. invested over the 12 months ending in its fourth quarter of 2013 $39 million

ROI has improved compared to -118.58% in the third quarter of 2013, due to net income growth.

Within the Healthcare sector 37 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the third quarter of 2013 from 0 to 221.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Dec 31 2013)
IV. Quarter		 0
III. Quarter		 (Jun 30 2013)
II. Quarter		 0
I. Quarter		 (Dec 31 2012)
FY
Y / Y Investment Change TTM 57.01 % 63.6 % 152.65 % 441.18 % -
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 71 26 34 26 29
Return On Investment (TTM) 89.96 % -118.58 % -115.68 % -241.5 % -251.07 %
GENT's Overall Ranking # 221 # 0 # 0 # 0 # 0
Seq. Investment Change TTM 36 % 0.67 % 7.88 % 6.3 % 41.72 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions 35 -34 -33 -64 -62

GENT Company Profile >> Back to GENT Roi Comparisons >> See Annual GENT Return On Investment



Return On Investment GENT's Ranking
Within: No.
Industry # 12
Sector # 38
Overall # 221

Return On Investment Statistics
High Average Low
48.34 %
-38.92 %
-126.17 %
(Dec 31 2013)   (Dec 31 2012)







Financial Statements
Gentium S.p.a.'s IV. Quarter Investments $ 71 Millions GENT's Balance sheet
Gentium S.p.a.'s IV. Quarter Income $ 33 Millions Quarterly GENT's Income Statement
GENT's Income by Division See GENT's Income by Division


GENT Annual Return On Investment (Dec 31 2013)
2013		 (Dec 31 2012)
2012		 (Dec 31 2009)
2011

Total Investments in Millions 70 29 25 0 0
Y / Y Investment Growth 143.98 % 14.39 % - - -
Net Income in Millions 33 1 4 0 0
Y / Y Net Income Growth 3182.9 % -73.64 % - - -
Annual Return On Investment 46.39 % 3.45 % 14.96 % - -


Annual Roi Comment
In the fiscal year 2013 ROI improved to 46.39 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
GENT's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for GENT's Competitors
Subscribers only: Roi for Gentium S.p.a.'s Suppliers
Subscribers only: Return On Investment for GENT's Customers

Other Ratios
GENT's Roa GENT's Inventory Turnover Ratio GENT's Growth Rates GENT's Dividend Statistics
GENT's Profitability Ratios GENT's Asset Turnover Ratio GENT's Dividend Growth
GENT's Roe GENT's Valuation Ratios GENT's Financial Strength Ratios GENT's Dividend Payout Ratio



Companies with similar Return On Investment at Dec 31 2013, within Healthcare Sector ROI
Acceleron Pharma inc  215.17 %
Glucotrack Inc   154.29 %
Sophiris Bio Inc.  151.42 %
Iveric Bio Inc   145.00 %
Biocorrx Inc   140.27 %
Brainstorm Cell Therapeutics inc   135.10 %
Bluebird Bio Inc   132.64 %
Cadence Pharmaceuticals Inc  109.32 %
Cyclo Therapeutics Inc   107.05 %
Savara Inc   102.58 %
Nanostring Technologies Inc   97.56 %
Epizyme Inc.  94.27 %
Coronado Biosciences Inc  91.24 %
Arena Pharmaceuticals Inc   71.29 %
Sorrento Therapeutics Inc   70.76 %
Filana Therapeutics Inc   70.27 %
China Yct International Group, Inc.  67.98 %
Oramed Pharmaceuticals Inc  67.10 %
Viskase Holdings inc   60.66 %
Portola Pharmaceuticals inc   59.24 %
Agios Pharmaceuticals Inc   54.47 %
Lightwave Logic Inc   52.30 %
Insys Therapeutics, Inc.  46.69 %
Gentium S.p.a.  46.34 %
Veru Inc   42.03 %
Oncomed Pharmaceuticals Inc  41.91 %
Milestone Scientific Inc   41.86 %
Camp4 Therapeutics Corporation  32.52 %
Guided Therapeutics Inc   30.24 %
Psychemedics Corporation  29.77 %

Date modified: 2026-09-10T02:29:34+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.